calendar
24 catalysts · 3,728 phase readout · 2,104 8k filing · 276 earnings · 172 phase 2 completion · 138 grant · 133 drug shortage
24 catalysts · 3,728 phase readout · 2,104 8k filing · 276 earnings · 172 phase 2 completion · 138 grant · 133 drug shortage
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Normal 180 Day Track No User Fee. Product code: MWG. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: QZH. Advisory committee: TX. Decision: APPR
Supplement type: Real-Time Process. Product code: NIK. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Normal 180 Day Track No User Fee. Product code: NAW. Advisory committee: RA. Decision: APPR
Supplement type: 30-Day Notice. Product code: MRA. Advisory committee: OR. Decision: OK30
Supplement type: 30-Day Notice. Product code: QPY. Advisory committee: PM. Decision: OK30
Supplement type: Real-Time Process. Product code: LWP. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: NVN. Advisory committee: CV. Decision: APPR
Supplement type: Normal 180 Day Track. Product code: DSQ. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Special (Immediate Track). Product code: NPW. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: NVN. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: QFV. Advisory committee: CV. Decision: APPR
Supplement type: Special (Immediate Track). Product code: QQK. Advisory committee: GU. Decision: APPR
Supplement type: 30-Day Notice. Product code: NJL. Advisory committee: OR. Decision: OK30
Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration
Therapy area: Ophthalmology. Indication: Choroidal Neovascularization
Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy
Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion
Therapy area: Ophthalmology. Indication: Diabetic Retinopathy
Therapy area: Ophthalmology. Indication: Diabetic Macular Edema